iloprost 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
prostaglandins	1422	78919-13-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: iloprost ciloprost endoprost ilomedin ventavis ZK36374 ZK-36374 ZK 36374	An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation. Molecular weight: 360.49 Formula: C22H32O4 CLOGP: 2.56 LIPINSKI: 0 HAC: 4 HDO: 3 TPSA: 77.76 ALOGS: -4.62 ROTB: 9 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

iloprost
ciloprost
endoprost
ilomedin
ventavis
ZK36374
ZK-36374
ZK 36374

An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation.

Molecular weight: 360.49
Formula: C22H32O4
CLOGP: 2.56
LIPINSKI: 0
HAC: 4
HDO: 3
TPSA: 77.76
ALOGS: -4.62
ROTB: 9

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.15	mg	Inhal.solution
50	mcg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	1 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.00 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	16 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.37 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	16 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.40 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.57 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 29, 2004	FDA	ACTELION PHARMS LTD

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Death	1123.58	17.96	910	18128	373471	63096513
Dyspnoea	465.09	17.96	758	18280	660555	62809429
Right ventricular failure	368.11	17.96	152	18886	17036	63452948
Fluid retention	272.79	17.96	188	18850	59498	63410486
Pulmonary hypertension	196.10	17.96	128	18910	36995	63432989
Cough	184.43	17.96	321	18717	292422	63177562
Cardiac failure	137.59	17.96	151	18887	88991	63380993
Syncope	125.56	17.96	165	18873	117220	63352764
Hospitalisation	120.80	17.96	138	18900	84943	63385041
Oxygen saturation decreased	112.98	17.96	136	18902	88449	63381535
Chest pain	112.00	17.96	218	18820	215741	63254243
Oedema peripheral	111.57	17.96	202	18836	189309	63280675
Transfusion	109.67	17.96	64	18974	15153	63454831
Headache	105.51	17.96	421	18617	632820	62837164
Oedema	94.85	17.96	131	18907	97491	63372493
Disease progression	92.29	17.96	146	18892	122612	63347372
Lung transplant	89.04	17.96	34	19004	3094	63466890
Rash	85.26	17.96	31	19007	560840	62909144
Dyspnoea exertional	82.51	17.96	96	18942	60206	63409778
Drug ineffective	76.25	17.96	123	18915	1044642	62425342
Hypotension	76.11	17.96	216	18822	272388	63197596
Pulmonary arterial pressure increased	74.23	17.96	31	19007	3564	63466420
Product dose omission issue	73.70	17.96	194	18844	234119	63235865
Alopecia	73.14	17.96	8	19030	337528	63132456
Pulmonary oedema	71.15	17.96	85	18953	54788	63415196
Cardiac failure congestive	70.91	17.96	111	18927	92322	63377662
Pain in jaw	69.34	17.96	75	18963	43421	63426563
Pulmonary arterial hypertension	69.15	17.96	56	18982	22521	63447463
Dizziness	66.69	17.96	280	18758	429645	63040339
Catheterisation cardiac	60.71	17.96	29	19009	4574	63465410
Hypervolaemia	59.92	17.96	57	18981	28356	63441628
Drug hypersensitivity	58.84	17.96	11	19027	310676	63159308
Joint swelling	57.16	17.96	14	19024	327652	63142332
Epistaxis	55.30	17.96	87	18951	72638	63397346
Laryngeal pain	55.28	17.96	27	19011	4471	63465513
Cardiac arrest	53.53	17.96	98	18940	92447	63377537
Respiratory failure	52.89	17.96	103	18935	101755	63368229
Rheumatoid arthritis	52.53	17.96	7	19031	253812	63216172
Throat irritation	49.92	17.96	59	18979	37588	63432396
Choking	49.53	17.96	33	19005	9846	63460138
Flushing	47.90	17.96	83	18955	75004	63394980
Treatment failure	47.80	17.96	3	19035	199040	63270944
Contraindicated product administered	47.52	17.96	5	19033	217643	63252341
Arthropathy	47.35	17.96	7	19031	234785	63235199
Arthralgia	46.31	17.96	62	18976	569648	62900336
Scleroderma	44.79	17.96	25	19013	5437	63464547
Musculoskeletal stiffness	43.69	17.96	3	19035	184615	63285369
Therapeutic product effect decreased	43.31	17.96	4	19034	193183	63276801
Pneumonia	41.45	17.96	256	18782	456511	63013473
Haemoptysis	41.40	17.96	47	18991	28679	63441305
Toxicity to various agents	40.39	17.96	12	19026	247238	63222746
Cardiac disorder	40.30	17.96	62	18976	50754	63419230
Nasal congestion	39.82	17.96	71	18967	65589	63404395
Influenza	39.31	17.96	95	18943	108627	63361357
Disease complication	38.65	17.96	19	19019	3190	63466794
Hypoxia	38.00	17.96	66	18972	59726	63410258
Cardiac pacemaker insertion	36.90	17.96	20	19018	4106	63465878
Asphyxia	36.79	17.96	23	19015	6158	63463826
Inappropriate schedule of product administration	36.68	17.96	90	18948	103875	63366109
Exercise tolerance decreased	36.67	17.96	22	19016	5475	63464509
Pain	35.85	17.96	109	18929	740519	62729465
Hypersensitivity	35.44	17.96	22	19016	292663	63177321
Concomitant disease aggravated	35.32	17.96	26	19012	9086	63460898
Off label use	35.01	17.96	96	18942	674366	62795618
Drug intolerance	34.95	17.96	25	19013	308636	63161348
Walking distance test abnormal	34.91	17.96	11	19027	563	63469421
Treatment noncompliance	34.58	17.96	49	18989	37276	63432708
Product cleaning inadequate	33.88	17.96	6	19032	20	63469964
Condition aggravated	33.11	17.96	220	18818	401997	63067987
Presyncope	32.69	17.96	41	18997	27744	63442240
Choking sensation	31.16	17.96	17	19021	3537	63466447
Cor pulmonale	30.35	17.96	14	19024	2040	63467944
Cyanosis	30.18	17.96	31	19007	16904	63453080
Product prescribing issue	29.61	17.96	15	19023	2684	63467300
Product supply issue	29.22	17.96	13	19025	1742	63468242
Systemic scleroderma	29.13	17.96	11	19027	970	63469014
Urticaria	29.04	17.96	7	19031	165795	63304189
Right ventricular dilatation	28.86	17.96	12	19026	1364	63468620
Pericarditis	28.76	17.96	3	19035	131576	63338408
Hepatic enzyme increased	27.70	17.96	13	19025	202315	63267669
Chest discomfort	26.66	17.96	83	18955	109886	63360098
Caesarean section	26.49	17.96	29	19009	17003	63452981
Systemic lupus erythematosus	26.27	17.96	15	19023	208903	63261081
Ascites	25.93	17.96	45	18993	40683	63429301
Abdominal cavity drainage	25.40	17.96	8	19030	409	63469575
Blood carbon monoxide increased	24.41	17.96	4	19034	7	63469977
Malaise	24.32	17.96	210	18828	415744	63054240
Drug delivery system malfunction	24.10	17.96	10	19028	1130	63468854
Cardiac operation	24.10	17.96	14	19024	3284	63466700
Palpitations	23.63	17.96	81	18957	112689	63357295
Pruritus	23.06	17.96	46	18992	361407	63108577
Bronchitis	22.99	17.96	86	18952	124849	63345135
Cardiopulmonary failure	22.92	17.96	14	19024	3598	63466386
Pericardial effusion	22.89	17.96	36	19002	30022	63439962
Pulmonary hypertensive crisis	22.63	17.96	7	19031	337	63469647
Glossodynia	22.26	17.96	13	19025	178863	63291121
Respiratory distress	22.25	17.96	38	19000	33913	63436071
Injection site pain	21.73	17.96	6	19032	129794	63340190
Nasal discomfort	21.72	17.96	15	19023	4745	63465239
Vascular resistance pulmonary decreased	21.48	17.96	5	19033	79	63469905
Mouth haemorrhage	21.14	17.96	17	19021	6766	63463218
Hypertension	21.04	17.96	32	19006	279271	63190713
N-terminal prohormone brain natriuretic peptide increased	20.80	17.96	11	19027	2150	63467834
Impaired healing	20.79	17.96	3	19035	102539	63367445
Ventricular assist device insertion	20.53	17.96	4	19034	25	63469959
White blood cell count decreased	20.53	17.96	8	19030	139096	63330888
Device malfunction	20.45	17.96	26	19012	17831	63452153
Incorrect product administration duration	20.33	17.96	21	19017	11525	63458459
Transplant	20.32	17.96	8	19030	790	63469194
Blister	19.94	17.96	7	19031	129807	63340177
Chronic obstructive pulmonary disease	19.74	17.96	52	18986	62634	63407350
Drug administered in wrong device	19.56	17.96	4	19034	33	63469951
Mechanical ventilation	19.53	17.96	9	19029	1309	63468675
Productive cough	19.46	17.96	52	18986	63156	63406828
Atrial flutter	19.46	17.96	19	19019	9753	63460231
Finger amputation	19.29	17.96	7	19031	552	63469432
Drug dose omission by device	19.29	17.96	14	19024	4787	63465197
Cardiomegaly	19.16	17.96	25	19013	17589	63452395
Left-to-right cardiac shunt	19.09	17.96	5	19033	131	63469853
Sinusitis	19.03	17.96	24	19014	226629	63243355
Confusional state	18.86	17.96	26	19012	236354	63233630
Osteoarthritis	18.84	17.96	3	19035	95340	63374644
Jugular vein distension	18.68	17.96	8	19030	978	63469006
C-reactive protein increased	18.67	17.96	3	19035	94704	63375280
Blood cholesterol increased	18.49	17.96	3	19035	94029	63375955
Sudden death	18.39	17.96	19	19019	10430	63459554
Overdose	18.03	17.96	6	19032	115072	63354912

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Death	761.99	25.78	571	5097	397478	34553785
Right ventricular failure	212.32	25.78	72	5596	8712	34942551
Fluid retention	137.50	25.78	73	5595	26814	34924449
Dyspnoea	123.93	25.78	219	5449	376563	34574700
Pulmonary hypertension	101.84	25.78	55	5613	20869	34930394
Cough	49.79	25.78	88	5580	150052	34801211
Oedema	49.20	25.78	48	5620	45693	34905570
Oedema peripheral	47.38	25.78	76	5592	119736	34831527
Oxygen saturation decreased	46.16	25.78	50	5618	53768	34897495
Hospitalisation	45.58	25.78	51	5617	56851	34894412
Cardiac failure	37.58	25.78	59	5609	91189	34860074
Transfusion	37.42	25.78	21	5647	8564	34942699
Flushing	36.69	25.78	35	5633	32385	34918878
Lung transplant	35.17	25.78	13	5655	2011	34949252
Pulmonary arterial hypertension	34.39	25.78	20	5648	8719	34942544
Condition aggravated	33.76	25.78	87	5581	192109	34759154
Neonatal pneumonia	33.40	25.78	7	5661	128	34951135
Neonatal hypotension	32.13	25.78	7	5661	155	34951108
Spontaneous intrahepatic portosystemic venous shunt	31.71	25.78	5	5663	15	34951248
Headache	30.39	25.78	86	5582	200549	34750714
Cardiac index increased	29.68	25.78	5	5663	25	34951238
Pain in jaw	29.36	25.78	21	5647	13019	34938244
Syncope	28.20	25.78	52	5616	91399	34859864
Heart transplant	27.84	25.78	9	5659	934	34950329
Dizziness	26.82	25.78	87	5581	218434	34732829

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Death	1230.50	18.91	1136	22346	565378	79155528
Dyspnoea	537.37	18.91	924	22558	856101	78864805
Right ventricular failure	514.49	18.91	210	23272	23287	79697619
Fluid retention	403.80	18.91	253	23229	69556	79651350
Pulmonary hypertension	257.30	18.91	166	23316	47914	79672992
Cough	223.05	18.91	392	23090	366397	79354509
Headache	146.40	18.91	473	23009	653299	79067607
Oedema peripheral	140.73	18.91	260	23222	252028	79468878
Transfusion	140.25	18.91	84	23398	21246	79699660
Oxygen saturation decreased	135.29	18.91	178	23304	128869	79592037
Oedema	133.25	18.91	170	23312	119410	79601496
Cardiac failure	125.78	18.91	189	23293	154653	79566253
Chest pain	119.13	18.91	259	23223	282045	79438861
Syncope	115.52	18.91	197	23285	179252	79541654
Hospitalisation	111.37	18.91	138	23344	94098	79626808
Lung transplant	107.43	18.91	43	23439	4518	79716388
Pain in jaw	101.52	18.91	94	23388	46057	79674849
Dizziness	86.79	18.91	345	23137	526096	79194810
Dyspnoea exertional	84.91	18.91	116	23366	86957	79633949
Pulmonary arterial pressure increased	83.80	18.91	36	23446	4519	79716387
Product dose omission issue	83.38	18.91	208	23274	247329	79473577
Disease progression	83.26	18.91	174	23308	184188	79536718
Catheterisation cardiac	78.98	18.91	37	23445	5691	79715215
Pulmonary arterial hypertension	78.85	18.91	66	23416	28300	79692606
Flushing	76.29	18.91	111	23371	88157	79632749
Toxicity to various agents	73.58	18.91	17	23465	421523	79299383
Throat irritation	72.41	18.91	74	23408	40872	79680034
Hypervolaemia	71.61	18.91	75	23407	42615	79678291
Cardiac failure congestive	69.71	18.91	139	23343	142263	79578643
Pulmonary oedema	67.74	18.91	105	23377	88149	79632757
Epistaxis	63.38	18.91	116	23366	111399	79609507
Rash	59.34	18.91	50	23432	578308	79142598
Choking	57.91	18.91	39	23443	12062	79708844
Drug ineffective	57.58	18.91	148	23334	1080765	78640141
Laryngeal pain	56.21	18.91	30	23452	6084	79714822
Drug hypersensitivity	54.27	18.91	11	23471	298905	79422001
Condition aggravated	52.57	18.91	288	23194	500836	79220070
Haemoptysis	50.68	18.91	72	23410	55927	79664979
Respiratory failure	48.71	18.91	140	23342	180771	79540135
Scleroderma	47.76	18.91	26	23456	5484	79715422
Cardiac disorder	45.99	18.91	75	23407	65682	79655224
Concomitant disease aggravated	45.91	18.91	35	23447	13132	79707774
Cor pulmonale	45.29	18.91	19	23463	2249	79718657
Drug delivery system malfunction	44.94	18.91	14	23468	703	79720203
Disease complication	44.76	18.91	24	23458	4913	79715993
Cardiac pacemaker insertion	43.72	18.91	25	23457	5797	79715109
Influenza	43.66	18.91	109	23373	129497	79591409
Acute kidney injury	41.90	18.91	55	23427	519349	79201557
Alopecia	40.98	18.91	9	23473	231346	79489560
Hypotension	40.85	18.91	245	23237	440072	79280834
Rheumatoid arthritis	39.25	18.91	7	23475	208463	79512443
Mechanical ventilation	38.55	18.91	18	23464	2746	79718160
Pneumonia	38.35	18.91	328	23154	659918	79060988
Exercise tolerance decreased	38.14	18.91	27	23455	9044	79711862
Nasal congestion	37.76	18.91	75	23407	76477	79644429
Inappropriate schedule of product administration	37.50	18.91	105	23377	133523	79587383
Musculoskeletal stiffness	37.36	18.91	4	23478	175004	79545902
Therapeutic product effect decreased	36.96	18.91	3	23479	163860	79557046
Walking distance test abnormal	36.36	18.91	12	23470	726	79720180
Cardiac operation	36.25	18.91	21	23461	4991	79715915
Joint swelling	36.15	18.91	20	23462	288626	79432280
Mouth haemorrhage	35.87	18.91	28	23454	10871	79710035
Pulmonary hypertensive crisis	35.58	18.91	10	23472	350	79720556
Arthralgia	35.41	18.91	72	23410	571731	79149175
Chest discomfort	34.43	18.91	104	23378	137940	79582966
Treatment failure	33.71	18.91	5	23477	170481	79550425
Pulmonary vascular resistance abnormality	33.38	18.91	8	23474	147	79720759
Cyanosis	33.18	18.91	39	23443	25143	79695763
Treatment noncompliance	33.06	18.91	57	23425	52211	79668695
Overdose	32.96	18.91	7	23475	184199	79536707
Contraindicated product administered	32.63	18.91	4	23478	157534	79563372
Caesarean section	32.44	18.91	28	23454	12507	79708399
Thrombocytopenia	32.32	18.91	19	23463	265240	79455666
Cardiac arrest	31.67	18.91	117	23365	171979	79548927
Drug interaction	30.45	18.91	47	23435	415136	79305770
Off label use	30.29	18.91	151	23331	907064	78813842
Product cleaning inadequate	30.16	18.91	5	23477	10	79720896
Transplant evaluation	29.87	18.91	13	23469	1684	79719222
Incorrect product administration duration	29.39	18.91	26	23456	11996	79708910
Product prescribing issue	29.39	18.91	17	23465	4028	79716878
Spontaneous intrahepatic portosystemic venous shunt	28.73	18.91	5	23477	15	79720891
Drug administered in wrong device	28.69	18.91	6	23476	57	79720849
Confusional state	28.45	18.91	31	23451	317966	79402940
Pancytopenia	28.25	18.91	7	23475	165738	79555168
Sudden death	28.23	18.91	34	23448	22477	79698429
Heart transplant	28.22	18.91	12	23470	1469	79719437
Malaise	28.19	18.91	243	23239	489626	79231280
Asphyxia	27.97	18.91	25	23457	11695	79709211
Chronic obstructive pulmonary disease	27.88	18.91	71	23411	85348	79635558
Product supply issue	27.53	18.91	13	23469	2035	79718871
Brain natriuretic peptide increased	27.44	18.91	22	23460	8878	79712028
Arthropathy	27.38	18.91	9	23473	177102	79543804
Choking sensation	27.28	18.91	16	23466	3890	79717016
Drug dose omission by device	27.20	18.91	19	23463	6231	79714675
White blood cell count decreased	26.69	18.91	11	23471	188277	79532629
Product use in unapproved indication	26.41	18.91	21	23461	250338	79470568
Product use issue	26.38	18.91	127	23355	209695	79511211
COVID-19	26.22	18.91	7	23475	157667	79563239
Hypoxia	25.94	18.91	78	23404	103165	79617741
Nasopharyngitis	25.92	18.91	145	23337	253736	79467170
Cardiac index increased	25.79	18.91	5	23477	31	79720875
Neonatal pneumonia	25.52	18.91	5	23477	33	79720873
Neonatal hypotension	25.39	18.91	5	23477	34	79720872
Lung disorder	25.30	18.91	66	23416	80491	79640415
Pain	25.29	18.91	114	23368	703688	79017218
Hypersensitivity	25.23	18.91	24	23458	262215	79458691
Right ventricular dilatation	25.20	18.91	12	23470	1914	79718992
C-reactive protein increased	25.01	18.91	4	23478	129023	79591883
Atrial septal defect repair	24.77	18.91	8	23474	452	79720454
Bronchitis	24.17	18.91	89	23393	130555	79590351
Leukopenia	24.02	18.91	3	23479	116510	79604396
Systemic scleroderma	23.81	18.91	10	23472	1187	79719719
Ventricular assist device insertion	23.50	18.91	5	23477	52	79720854
Palpitations	23.21	18.91	86	23396	126524	79594382
Device malfunction	23.07	18.91	30	23452	21418	79699488
Urticaria	22.93	18.91	13	23469	185188	79535718
Respiratory disorder neonatal	22.62	18.91	5	23477	63	79720843
Transplant	22.01	18.91	9	23473	999	79719907
Heart and lung transplant	21.86	18.91	6	23476	192	79720714
Vascular resistance pulmonary decreased	21.40	18.91	5	23477	82	79720824
Hypertension	21.03	18.91	41	23441	330951	79389955
Premature delivery	20.97	18.91	30	23452	23437	79697469
Pulmonary veno-occlusive disease	20.74	18.91	10	23472	1638	79719268
Pericarditis	20.73	18.91	3	23479	104233	79616673
Rhabdomyolysis	20.44	18.91	3	23479	103128	79617778
Vascular resistance pulmonary increased	20.32	18.91	5	23477	103	79720803
Blood pressure decreased	20.31	18.91	70	23412	99396	79621510
Drug intolerance	20.22	18.91	29	23453	264090	79456816
Abdominal cavity drainage	20.15	18.91	8	23474	822	79720084
Chemotherapy	20.14	18.91	10	23472	1747	79719159
Left-to-right cardiac shunt	20.10	18.91	5	23477	108	79720798
Pericardial effusion	20.08	18.91	43	23439	46194	79674712
Nasal discomfort	20.05	18.91	15	23467	5468	79715438
Heart rate increased	19.67	18.91	79	23403	120645	79600261
Hepatic enzyme increased	19.65	18.91	15	23467	182595	79538311
Dry throat	19.51	18.91	17	23465	7689	79713217
Organ transplant	19.31	18.91	3	23479	3	79720903
Deep vein thrombosis	18.94	18.91	6	23476	120913	79599993

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	B01AC11	BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Platelet aggregation inhibitors excl. heparin
FDA CS	M0017817	Prostaglandins I
FDA EPC	N0000175603	Prostacycline
CHEBI has role	CHEBI:35620	vasodilator agents
CHEBI has role	CHEBI:50427	platelet aggregation inhibitors
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D006401	Hematologic Agents
MeSH PA	D010975	Platelet Aggregation Inhibitors
MeSH PA	D014665	Vasodilator Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Pulmonary arterial hypertension	indication	11399002
Bronchospasm	contraindication	4386001
Chronic obstructive lung disease	contraindication	13645005	DOID:3083
Pulmonary edema	contraindication	19242006	DOID:11396
Low blood pressure	contraindication	45007003
Hepatic failure	contraindication	59927004
Mild to Moderate Hypotension	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.83	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Prostacyclin receptor	GPCR	P43119	PI2R_HUMAN	AGONIST	EC50	7.75	WOMBAT-PK	CHEMBL
Prostaglandin F2-alpha receptor	GPCR	P43088	PF2R_HUMAN	AGONIST	Ki	6.20	IUPHAR
Prostaglandin E2 receptor EP1 subtype	GPCR	P34995	PE2R1_HUMAN		EC50	7.70	WOMBAT-PK
Prostaglandin E2 receptor EP3 subtype	GPCR	P43115	PE2R3_HUMAN		EC50	7.30	WOMBAT-PK
Thromboxane A2 receptor	GPCR	P21731	TA2R_HUMAN	AGONIST	Ki	5.20	IUPHAR
Prostaglandin E2 receptor EP2 subtype	GPCR	P43116	PE2R2_HUMAN	AGONIST	Ki	5.70	IUPHAR
Prostaglandin E2 receptor EP4 subtype	GPCR	P35408	PE2R4_HUMAN	AGONIST	Ki	6.68	IUPHAR
Prostaglandin D2 receptor	GPCR	Q13258	PD2R_HUMAN	AGONIST	Ki	6.60	IUPHAR
Prostaglandin E2 receptor EP1 subtype	GPCR		PE2R1_MOUSE	AGONIST	Ki	7.70	IUPHAR
Prostaglandin E2 receptor EP2 subtype	GPCR		PE2R2_MOUSE	AGONIST	Ki	5.80	IUPHAR
Prostaglandin E2 receptor EP3 subtype	GPCR		PE2R3_MOUSE	AGONIST	Ki	7.66	IUPHAR
Prostaglandin E2 receptor EP4 subtype	GPCR		PE2R4_MOUSE	AGONIST	Ki	5.60	IUPHAR
Prostaglandin E2 receptor EP2 subtype	GPCR		PE2R2_RAT	AGONIST	Ki	5.90	IUPHAR
Prostacyclin receptor	GPCR		PI2R_MOUSE	AGONIST	Ki	8	IUPHAR
Prostacyclin receptor	GPCR		PI2R_RAT		EC50	9.16	CHEMBL
Prostaglandin E2 receptor EP3 subtype	GPCR		PE2R3_RAT	AGONIST	EC50	9.20	IUPHAR
Prostaglandin E2 receptor EP1 subtype	GPCR		PE2R1_RAT	AGONIST	Ki	7.90	IUPHAR

External reference:

ID	Source
4024905	VUID
N0000171024	NUI
D02721	KEGG_DRUG
4024905	VANDF
C0079594	UMLSCUI
CHEBI:63916	CHEBI
CHEMBL494	ChEMBL_ID
DB01088	DRUGBANK_ID
D016285	MESH_DESCRIPTOR_UI
5311181	PUBCHEM_CID
1895	IUPHAR_LIGAND_ID
4972	INN_ID
JED5K35YGL	UNII
40138	RXNORM
19138	MMSL
52233	MMSL
64085	MMSL
d05232	MMSL
005258	NDDF
319452005	SNOMEDCT_US
395740002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
VENTAVIS	HUMAN PRESCRIPTION DRUG LABEL	1	66215-302	SOLUTION	10 ug	RESPIRATORY (INHALATION)	NDA	31 sections
VENTAVIS	HUMAN PRESCRIPTION DRUG LABEL	1	66215-302	SOLUTION	10 ug	RESPIRATORY (INHALATION)	NDA	31 sections
VENTAVIS	HUMAN PRESCRIPTION DRUG LABEL	1	66215-302	SOLUTION	10 ug	RESPIRATORY (INHALATION)	NDA	31 sections
VENTAVIS	HUMAN PRESCRIPTION DRUG LABEL	1	66215-303	SOLUTION	20 ug	RESPIRATORY (INHALATION)	NDA	31 sections
VENTAVIS	HUMAN PRESCRIPTION DRUG LABEL	1	66215-303	SOLUTION	20 ug	RESPIRATORY (INHALATION)	NDA	31 sections
VENTAVIS	HUMAN PRESCRIPTION DRUG LABEL	1	66215-303	SOLUTION	20 ug	RESPIRATORY (INHALATION)	NDA	31 sections